Supporting the development of drugs for rare diseases - the importance of regulatory transparency

New England Journal of Medicine

1 March 2025 - Transparency regarding the information submitted to the FDA and the agency’s decision making could have far-reaching benefits for drug development.

Read New England Journal of Medicine Perspective

Michael Wonder

Posted by:

Michael Wonder